Quoin Pharmaceuticals Unveils New Episode in Patient Awareness Series
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has launched the second episode of its enlightening video series titled "Living with Netherton." This initiative is part of the broader NETHERTON NOW awareness campaign, which aims to shine a light on the experiences of those living with Netherton Syndrome. The latest episode showcases a remarkable patient journey spanning 79 years, focusing on the life of Norma Coles, a 79-year-old woman who has witnessed the challenges and triumphs associated with this rare genetic disorder.
Highlighting Norma Coles' Journey with Netherton Syndrome
In this poignant video, viewers are introduced to Norma, whose diagnosis with Netherton Syndrome came after decades of misdiagnosis and struggles with severe skin conditions. Throughout her life, she endured fragile skin, painful rashes, and brittle hair, which is often a hallmark of the disorder. It wasn’t until her mid-50s that she learned she was diagnosed with Netherton Syndrome, reconnecting her to the historical context of her condition.
The Search for Diagnosis and Awareness
Norma’s early interactions with Dr. Edward Netherton himself highlight the long history of the disease and the urgent need for increased awareness and understanding in the medical community. "I guess I got it all started," she reflects in the video, expressing her surprise at discovering her connection to the pioneering research conducted on her condition.
The Importance of the NETHERTON NOW Campaign
Quoin Pharmaceuticals is dedicated to enhancing awareness, education, and advocacy for individuals affected by Netherton Syndrome. The NETHERTON NOW campaign aims to bring attention to the often-overlooked challenges of those with the disorder. By sharing real patient experiences, Quoin hopes to foster empathy and understanding toward those who often feel unheard.
Advocating for Treatment and Research
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, emphasizes the significance of Norma's story in bridging the gap between historical and contemporary narratives of Netherton Syndrome. "Her powerful story reflects the reality of so many others who continue to go undiagnosed and unsupported," Carter says, underscoring the importance of effective treatments.
Developing a Transformative Treatment
Quoin's commitment to this cause is apparent through its research and development efforts for QRX003, a groundbreaking therapy targeted at treating Netherton Syndrome. Currently, QRX003 is undergoing four clinical trials, with preliminary results showing promise in enhancing skin healing and reducing inflammation and itchiness.
The Future of QRX003 and Patient Care
Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin, notes the significance of Norma's experiences in motivating the company's mission. With no FDA-approved treatments available for Netherton Syndrome, the urgency of their clinical trials remains high. "Stories like Norma’s fuel our determination every step of the way," he declares, promoting a future where patients receive the care and treatment they deserve.
Support and Advocacy for Patients
Quoin's mission extends beyond the development of medications, as the company actively works to support the community of individuals and families affected by Netherton Syndrome. Their team focuses on providing educational resources and advocacy initiatives to address the needs of those facing this condition.
Building a Community of Hope
The awareness raised through initiatives like the NETHERTON NOW campaign helps create a supportive environment for patients and caregivers alike. By highlighting personal stories and struggles, Quoin seeks to cultivate a sense of community, fostering connections among those who share similar experiences.
Conclusion: A Call to Action for Netherton Syndrome Awareness
The second episode of the "Living with Netherton" series is a reminder of the importance of sharing patient stories, as these narratives not only educate but serve as a beacon of hope for others facing similar battles. As Quoin Pharmaceuticals continues its journey to find effective treatments, it strives to ensure that voices like Norma's are amplified, bringing greater awareness to Netherton Syndrome.
Frequently Asked Questions
What is Quoin Pharmaceuticals working on for Netherton Syndrome?
Quoin Pharmaceuticals is focused on developing QRX003, a topical treatment for Netherton Syndrome, which is currently in clinical trials.
Who is featured in the latest episode of the series?
The latest episode highlights the story of Norma Coles, a 79-year-old woman diagnosed with Netherton Syndrome after years of misdiagnosis.
What is the aim of the NETHERTON NOW campaign?
The NETHERTON NOW campaign aims to raise awareness, improve education, and support advocacy efforts for individuals affected by Netherton Syndrome.
How does QRX003 work?
QRX003 is designed to mimic the function of a specific protein involved in skin barrier integrity, addressing symptoms associated with Netherton Syndrome.
Where can I find more information about Quoin Pharmaceuticals?
For more information about Quoin Pharmaceuticals and its initiatives, you can visit their official site or the NETHERTON NOW campaign page.
